Recently, AstraZeneca announced on its official website the results of the MYSTIC test of Imfinzi (Durvalumab) combined with tremelimumab in the treatment of stage IV non-small cell lung cancer, and ultimately did not reach the end point of improving the overall survival (OS). The data were not statistically significant. Following last year's MYSTIC trial failed to reach the primary end point of improving PFS, the failure of the OS endpoint was no different than expected. In this regard, some insiders said: "AstraZeneca's individual projects in the field of non-small cell lung cancer will affect the market side to a certain extent, and Imfinzi's dream of becoming a super heavy may be gradually drifting away." It is understood that the MYSTIC trial is a randomized, open-label, multicenter, global clinical trial of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic (stage IV) In patients with non-small cell lung cancer (NSCLC), to evaluate the efficacy and safety of Imfinzi monotherapy and its combination therapy with tremelimumab (CTLA-4 antibody) versus standard care (SoC) platinum-based chemotherapy. The trial was conducted in 167 centers in 17 countries, including the United States, Canada, Europe, Russia, Australia, and parts of Asia (Japan, Korea, Thailand, Taiwan, and Vietnam). The main clinical endpoints included progression-free survival (PFS) and Overall survival (OS). In July 2017, AstraZeneca announced that the MYSTIC Phase III clinical study progression-free survival (PFS) failed to reach the pre-set primary study endpoint: patients with a PD-L1 tumor proportional score (TPS) ≥ 25% In contrast, Imfinzi+tremelimumab immunological combination failed to achieve the primary endpoint of improving PFS compared with SoC platinum-containing chemotherapy; in terms of secondary endpoint, although not formally evaluated, it was initially concluded that Imfinzi monotherapy did not reach pre-set relative to SoC PFS benefit threshold. Continued assessment of the total survival (OS) of the other two major study endpoints in the Imfinzi monotherapy and Imfinizi combination groups is the key to determining the ultimate success of the trial. Although she is again disappointed with non-small cell lung cancer, AstraZeneca has expressed her disappointment and will continue to pay attention to the research of non-small cell lung cancer treatment. AstraZeneca stressed that in the Imfinzi monotherapy group, the patient mortality risk-to-HR ratio reached 0.76 (97.54% confidence interval 0.564-1.019), P=0.036, very close to the study. The preset threshold. "We are still very pleased to see that IMFINZI shows similar activity to other PD-1 antibodies in patients with newly diagnosed non-small cell lung cancer (stage IV)." At the same time, in the Imfinzi combined with the Tremelimumab group, the HR value was 0.85 (98.77% confidence interval 0.611-1.173; p=0.202), and this data suggests that some specific populations may benefit from it. Support researchers to conduct further subgroup analyses of patients. In fact, Imfinzi (durvalumab) is a PD-L1 immunotherapy that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, counteracting the immune evasion strategy of tumors, thereby exerting an inhibitory effect. Based on clinical phase III PACIFIC trial data, Imfinzi has been approved for marketing in more than 40 countries and regions including the United States, the European Union, and Japan for the treatment of unresectable stage III NSCLC patients. This is the first and only Approved for the treatment of stage III lung cancer, AstraZeneca reported in the third quarter of this year that Imfinzi's sales reached 371 million US dollars, the industry analysis, which is inseparable from the approval of new indications. At the same time, Imfinzi is also approved for advanced bladder cancer patients treated in the United States, Canada, Brazil, Israel, India, United Arab Emirates, Australia and Hong Kong. In addition, Imfinzi monotherapy and its combination therapy with tremelimumab (CTLA-4 antibody), as a major developmental drug for AstraZeneca, are also undergoing small cell lung cancer (SCLC), bladder cancer, head and neck cancer and other solid tumors. Clinical Trials. Children's masks, medical surgical disposable children's medical masks, three-layer masks, unique packaging for girls and boys, and for children. Buy masks, certify us, and guarantee authenticity. Three-layer filtration, medical quality. Three-dimensional protection, multi-layer filtration, medical quality, breathable and skin-friendly. Plastic nose clip. The outer non-woven fabric blocks droplets, dust, etc., so that every breath of the child is more at ease. Intermediate filter cloth, flannel cloth filter particles, bacteria, etc. The inner non-woven fabric is skin-friendly, comfortable and more breathable. Kids Nonwoven Mask,Protective Disposable Face Mask,Anti Dust Activated Disposable Face Mask,Protective Children Face Mask KUTA TECHNOLOGY INDUSTRY CO.,LIMITED , https://www.kutasureblue.com
China Kids Nonwoven Mask,Protective Disposable Face Mask manufacturers, welcome Anti Dust Activated Disposable Face Mask,Protective Children Face Mask purchasers from worldwide to visit our site.